electroCore Expands Intellectual Property Portfolio With U.S. Patent No. 11,894,148 entitled "Systems And Methods For Treating Patients With Diseases Associated With Viruses"
Portfolio Pulse from Benzinga Newsdesk
electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company, announced the issuance of U.S. Patent No. 11,894,148 for treating disorders associated with the Coronaviridae family (COVID) using electrical impulses. The patent covers methods of reducing C-reactive protein levels in the blood by applying electrical impulses to the vagus nerve.
February 06, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
electroCore, Inc. received a new U.S. patent for a method of treating COVID-related disorders, potentially enhancing its product portfolio and market position.
The issuance of a new patent strengthens electroCore's intellectual property portfolio, potentially opening new markets or enhancing its competitive edge in the bioelectronic medicine sector. This could lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100